Welcome to our dedicated page for Revive Therapeutics news (Ticker: RVVTF), a resource for investors and traders seeking the latest updates and insights on Revive Therapeutics stock.
Revive Therapeutics Ltd. develops specialty life sciences programs focused on infectious diseases and medical countermeasures. Company news commonly centers on Bucillamine, including intellectual-property filings, granted patent coverage, and research updates on its potential use in infectious diseases and nerve-agent exposure.
Revive updates also cover work with Defence R&D Canada – Suffield Research Centre, botanical research compounds, molecular hydrogen therapeutic programs, and financing activity. Capital-structure news includes private placements, debt settlement, unit issuances, common share purchase warrants, compensation options, and the use of proceeds for working capital and trade payables.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Revive Therapeutics Ltd. (OTCQB: RVVTF) recently provided an update on its FDA Phase 3 clinical trial, evaluating Bucillamine for treating mild to moderate COVID-19. Following discussions with the FDA, the company has opted to have the Data Safety Monitoring Board (DSMB) review efficacy data from around 500 subjects. The DSMB's recommendation could lead to either continuation or early termination of the study based on statistical significance trends. Revive aims to explore regulatory pathways for Bucillamine, including potential collaborations for international approvals and clinical studies targeting Long COVID and related conditions. The company will also work on reformulating Bucillamine to expand its therapeutic applications, while not making any claims of curing COVID-19.
Revive Therapeutics Ltd. (OTCQB: RVVTF) announced the purchase of MDMA from PharmAla Biotech to support upcoming IND-enabling studies for its novel transdermal microneedle patch. The patch aims to deliver 3,4-Methylenedioxymethamphetamine (MDMA) and is expected to offer flexible drug delivery capacities and improved pharmacokinetics compared to oral dosing. Additionally, Revive is finalizing clinical development plans and collaborating with PharmaTher to enhance its research efforts. Results from recent studies will be crucial for regulatory discussions and potential commercial opportunities in mental health treatment.